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Abstract
Sialoadhesin (Sn, Siglec-1, CD169) is a member of the sialic acid binding Ig-like lectin (siglec) family expressed on
macrophages. Its macrophage specific expression makes it an attractive target for delivering antigens to tissue
macrophages via Sn-mediated endocytosis. Here we describe a novel approach for delivering antigens to macrophages
using liposomal nanoparticles displaying high affinity glycan ligands of Sn. The Sn-targeted liposomes selectively bind to
and are internalized by Sn-expressing cells, and accumulate intracellularly over time. Our results show that ligand decorated
liposomes are specific for Sn, since they are taken up by bone marrow derived macrophages that are derived from wild type
but not Sn
2/2 mice. Importantly, the Sn-targeted liposomes dramatically enhance the delivery of antigens to macrophages
for presentation to and proliferation of antigen-specific T cells. Together, these data provide insights into the potential of
cell-specific targeting and delivery of antigens to intracellular organelles of macrophages using Sn-ligand decorated
liposomal nanoparticles.
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Introduction
Sialoadhesin (Sn, Siglec-1, CD169) is a macrophage-restricted
surface receptor that recognizes sialic acid ligands and is conserved
in human and mouse [1]. High levels of Sn/CD169 expression
have been detected on resident macrophages and inflammatory
macrophages in tissues obtained from patients with multiple
sclerosis and rheumatoid arthritis [2]. Recent reports have shown
that Sn/CD169 is involved in macrophage internalization of sialic
acid carrying pathogens, suggesting that Sn/CD169 is an
endocytic receptor [3,4]. The fact that macrophages are profes-
sional antigen presenting cells has raised the possibility that
targeting antigens to macrophages via Sn/CD169 would elicit
antigen specific immune responses and improve host responses
against poor immunogenic antigens [5,6].
Using a porcine model, two recent reports have employed anti-
Sn/CD169 antibodies to assess the potential of targeting antigens
to Sn/CD169 expressing macrophages [5,6]. Delputte et. al used
an immunoconjugate comprising albumin linked to an anti-
porcine-Sn antibody [5]. In another report, a murine anti-Sn
antibody was used as the antigen to generate anti-murine Ig
antibodies [6]. Both reports documented augmented immune
responses and antibody production to the respective antigens
relative to immunization with the antigens alone (albumin and
murine IgG, respectively).
As an alternative to delivering antigens to macrophages using
Sn-antibodies, we have explored the possibility of targeting
antigens to macrophages using high affinity glycan ligands of Sn.
To date this approach has been hampered by lack of a suitable
platform that presents specific glycan ligands in a multivalent
context that is also capable of carrying the antigen of choice [7–
10]. Recently we reported the successful in vivo targeting of B
lymphoma cells using doxorubicin-loaded liposomal nanoparticles
decorated with glycan ligands of CD22, a B cell specific siglec [11].
Here we have adapted this platform for targeting antigens to Sn/
CD169 expressing macrophages by encapsulating the antigen in
the lumen of a liposome decorated with high affinity ligands
specific for Sn. The multivalent presentation of glycan ligands of
Sn/CD169 on the liposomes generates sufficient avidity to target
macrophages and be efficiently endocytosed. Moreover, we show
that liposome delivered antigen is efficiently presented to antigen-
specific T cells. Our findings provide insights into targeting Sn/
CD169 for delivery of antigen to tissue macrophages, and the
potential for targeting Sn/CD169 macrophages to investigate their
role as versatile antigen presenting cells in the innate and adaptive
immune responses.
Materials and Methods
Ethics Statement
The Scripps Office for the Protection of Research Subjects,
Institutional Review Board (IRB) has approved the use of blood
from normal donors in this research. Human blood was obtained
from The Scripps Research Institute’s Normal Blood Donor
Service (NBDS).
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Use Committee (IACUC) has approved all animal protocols use in
this research.
Liposome Preparation
Lipids used in this study were purchased from Avanti Polar
Lipids (Alabaster, AL) and NOF Corp (White Plains, NY). The
Sn/CD169 ligand, 9-N-biphenylcarboxyl-NeuAca2-3Galb1-
4GlcNAc-ethyl amine (39-
BPCNeuAc) was prepared as previously
described [12]. The 39-
BPCNeuAc-pegylated lipid was prepared by
coupling 39-
BPCNeuAca2-3Galb1-4GlcNAc-ethyl amine with N-
hydroxysuccinimide (NHS)-activated pegylated lipids. Liposomes
were prepared as previously described [11]. Non-targeted naked-
liposomes were composed of DSPC: Cholesterol: PEG-DSPE in a
60:35:5 molar ratio. Sn-targeted 39-
BPCNeuAc-liposomes substi-
tuted 39-
BPCNeuAc-PEG-DSPE for PEG-DSPE on a mol for mol
basis. To prepare fluorescently labeled liposomes, 1 mol% of
NBD-phosphoethanolamine or 0.2 mol% of Alexa Fluor647-PEG-
DSPE made by NHS-coupling with amine-PEG-DSPE was added
into the lipid mixture. Doxorubicin-loaded liposomes were used in
the pharmacokinetics study. Remote loading of doxorubicin
(Sigma) was obtained using gradients of ammonium sulfate [13].
To prepare ovalbumin-loaded liposomes, lipids were hydrated in
solution containing 5 mg/ml OVA (Sigma) followed by liposome
extrusion. Unbound OVA was removed from liposomes by
passing the suspensions through a Sepharose CL-4B (GE
Healthcare, Piscataway, NJ) column. The eluted fractions were
collected in tubes (0.3 ml per tube) and determined for OVA
concentration using a Bio-Rad Protein Assay kit. The loading
efficiency of liposomal OVA was approximately 20,30%.
Liposomes prepared using this method had a mean particle size
of 100610 nm in diameter and were confirmed by a Malvern
particle sizer instrument (Westborough, MA).
Cell Lines
THP-1 cells over-expressing human Sn (TSn) cells were a gift
from Dr. Hans Rempel and Dr. Lynn Pulliam (University of
California, San Francisco) [14]. TSn cells were maintained in
RPMI-1640 supplemented with 10% heat-inactivated fetal calf
serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin,
2 mM glutamine, 50 mM 2-mercaptoethanol, and 5 mg/ml
Blasticidin S (Invivogen, San Diego, CA). CHO-K1, Daudi
(Burkitt’s B lymphoma), BW5147 (mouse thymoma), and L929
(mouse fibroblast cell line) were obtained from ATCC and
maintained in the same medium used for TSn without Blasticidin
S. CHO cell lines expressing murine Sn/CD169 and human
Siglec-9 and 10 were generously provided by Dr. Paul Crocker
(University of Dundee, UK) and Dr. Yasuhiro Hashimoto
(Fukushima Medical University, Fukushima, Japan) [15]. They
were maintained in F10 medium supplemented as above with
0.5 mg/ml Geneticin (Invitrogen) instead of Blasticidin S. CHO
cells expressing Siglec-F, and human CD22 and Siglec-8 were
maintained as described [11,16]. The retrovirus-packaging cell
line Plat-E was obtained from Dr. Kazuo Yamamoto (The
university of Tokyo, Japan) under the permission from Dr. Toshio
Kitamura (The university of Tokyo, Japan) and maintained as
described [17].
Transfection of the CHO Cells with Siglec-E
Full length of Siglec-E were subcloned into into pcDNA5/FRT.
The Flp-In CHO cell line (Invitrogen) were transfected with
pcDNA5/FRT-Siglec-E to establish CHO cell lines stably
expressing Siglec-E. Transfected cells were cultured in DMEM/
F12 supplemented as above with 0.5 mg/ml Hygromycin-B
(Roche Applied Science, Indianapolis, IN) instead of Blasticidin S.
Transduction of the BW5147 Cells with Siglec-G
cDNA for Siglec-G was a generous gift from Dr. Lars Nitschke
(University of Erlangen, Germany). The extracellular and
transmembrane region of Siglec-G (amino acids 18–571) was
subcloned into the pMXs-IRES-EGFP-Myc-CD3f vector, which
allows the expression of the N-terminal Myc-tagged Siglec-G/
CD3f fusion proteins on cell surface with the bicistronic
expression of EGFP. Two days after transfecting Plat-E cells with
pMXs-IG-Myc-Siglec-G-CD3f plasmids by Lipofectamin 2000
(Invitrogen), the culture supernatant was harvested and added to
BW5147 cells with 8 mg/ml Polybrene (Millipore, Bedford, MA).
BW5147 cells expressing EGFP were sorted to more than 95% by
the FACSVantage SE (BD biosciences, San Jose, CA).
Liposome Binding Assay
Cell lines or mouse primary cells were incubated with the
fluorescently-labeled liposomes for the indicated period at 37uC.
The stained cells were washed with HBSS containing 0.1% BSA,
1 mM MgSO4, and 1.3 mM CaCl2 (FACS buffer) and analyzed
by flow cytometry with the exclusion of dead cells by propidium
iodide staining. More than 10,000 total cell counts were acquired
by FACS Caliber and LSRII (BD Bioscience) and data were
analyzed by FlowJo (Tree Star, San Carlos, CA). In some
experiments cells were incubated with liposomes in the mouse or
human serum (MP Biomedicals, Solon, OH). For determining
liposome internalization, liposome-stained TSn cells were washed
with either FACS buffer or 0.133 M citric acid buffer (pH 3.3)
that removes cell surface liposomes prior to FACS analysis.
Fluorescence Microscopy
For liposome co-localization assay, CHO cells expressing mSn/
CD169 were plated to a cover slip to achieve a 90% confluence
and stained with fluorescent liposomes at 37uC for 1.5 hr. After
removing unbound liposomes, cells were fixed with 4% parafor-
maldehyde and stained with biotin-conjugated anti-mouse Sn/
CD169 (clone: MOMA-1) for 1 hr at 25uC. For detecting early
endosomes and lysosomes, fixed cells were permeabilized with
0.05% saponin and stained with anti-EEA1 (BD Pharmingen) or
anti-lysosome (clone: UH3) antibodies. After washing with buffer,
cells were stained with an Alexa555 conjugated secondary
antibody (Invitrogen). Finally, the specimens were mounted on a
slide using mounting solution containing DAPI that stains nuclei.
Images were taken using a Zeiss fluorescence microscope, an
Axiocam camera (Carl Zeiss) and Axiovision 4 acquisition
software. For additional information please see Methods S1.
Generation of Mouse Bone Marrow Derived
Macrophages (BMM)s
C57BL/6J mice were purchased from The Scripps Research
Institute (TSRI) animal breeding facility. Sn
2/2 mice were kindly
provided by Dr. Ajit Varki (UCSD, San Diego) with the
permission from Dr. Paul Crocker (University of Dundee, UK).
All mice were maintained in pathogen-free conditions and were
used in accordance to the guidelines of the Institutional Animal
Care and Use Committee. Bone marrow cells from C57BL/6J
wild type and Sn
2/2 mice were harvested and differentiated into
macrophages in vitro with RPMI-1640 medium containing 10%
heat-inactivated FCS, 2 mM glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin, 1 mM non-essential amino acid, 1 mM
sodium pyruvate, 50 mM 2-melcaptoethanol, 20 mM HEPES and
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conditioned medium [18]. On day 7, IFN-a (500 IU/ml, R&D
Systems) was added to the culture for 2 additional days to induce
Sn/CD169 expression. To check Sn/CD169 expression on
macrophages, cells were harvested and blocked with anti-mouse
CD16/32 (2.4G2, BD Biosciences) prior to detecting with
fluorescence conjugated anti-Sn and anti-F4/80 (BM8, Biolegend,
San Diego, CA). The stained cells were washed with FACS buffer
and analyzed by flow cytometry as described above.
OT-II T Cell Proliferation Assay
OT-II TCR transgenic mice on C57BL/6J background were
provided by Dr. Charles Surh (TSRI, La Jolla, CA). CD4
+ T cells
were purified from the spleen of OT-II mice using a CD4
+ T cell
negative selection magnetic column (Miltenyi Biotec, Auburn, CA)
followed by labeling with carboxyfluorescein diacetate succinimi-
dyl ester (CFDA-SE, Invitrogen). Naı ¨ve or IFN-a stimulated
BMMs were incubated with OVA antigen alone, naked or
39-
BPCNeuAc liposomes carrying same amount of OVA (1 mg/ml)
at 37uC for 1 hr. BMMs were washed thoroughly to remove
unbound OVA before added to CFDA-labeled OT-II T cells at a
BMMs to T cells ratio of 1:20. After 3-day culture in vitro, cells
were harvested and co-stained with anti-CD4 (GK1.5, Biolegend)
prior to FACS analysis for T cell proliferation. Dead cells were
excluded using propidium iodide staining.
Sn Recycling Assay
Recycling properties of Sn were analyzed as previously
described [19]. Briefly, CHO cells expressing mSn were incubated
with unlabeled anti-Sn antibody (3D6, AbD Serotec) or isotype-
matched control antibody for 60 min at 37uC to allow internal-
ization of the bound antibody. Cells were then cooled at 4uCt o
stop the internalization and washed with either FACS buffer or
acidic buffer as described above to strip the anti-Sn antibody from
the cell surface. The live cells were then stained with anti-rat IgG-
Alexa488 (Life Technologies) to detect the unlabeled anti-Sn
antibody on the cell surface. To assess Sn recycling, the cells
washed with acidic buffer were further incubated for 30 min at
37uC to allow recycling of the internalized unlabeled antibody
back to the cell surface, or at 4uC as a control where no recycling
can occur. The cells were then cooled to 4uC stained with
secondary labeled anti-rat IgG antibody as described above and
analyzed by flow cytometry.
Statistical Analysis
We performed ANOVA and two-sample t-test for statistical
analysis.
Results
Sn-targeted Liposomes are Selectively Bound to and
Efficiently Internalized by Sn-expressing Cells
Sn/CD169 has a known preference for binding to ligands
bearing a2-3 linked sialic acids on glycans of glycoproteins and
glycolipids. We previously identified a high-affinity glycan ligand
(9-N-biphenylcarboxyl-NeuAca2-3Galb1-4GlcNAc,
39-
BPCNeuAc) of Sn/CD169 using a sialoside analogue array
[1,12]. To prepare Sn-targeted liposomes, we coupled
39-
BPCNeuAc ligands to a pegylated phospholipid (Figure 1) and
the corresponding 39-
BPCNeuAc pegylated lipid was formulated
with cholesterol and other phospholipids to make liposomes. In
flow cytometric assays, fluorescently labeled 39-
BPCNeuAc lipo-
somes exhibited a specific binding to Sn-expressing TSn cells and
did not bind to Daudi cells that express human CD22 (Siglec-2),
whereas the non-targeted naked liposomes showed no binding to
either (Figure 2A). Next we compared the kinetics of binding and
uptake of anti-Sn antibody and the 39-
BPCNeuAc liposomes at
37uC. As shown in Figure 2B, binding of both antibody and
39-
BPCNeuAc liposomes was evident at 5 minutes, but while the
amount of bound antibody remained constant, the amount of
39-
BPCNeuAc liposomes increased 5–10 fold over the next 90
minutes. As documented previously for CD22 (Siglec-2) [19], these
observations are consistent with release of the endocytosed
liposomes in the acidic endosomes, and recycling of the ‘empty’
receptor to pick up another load of cargo at the cell surface [19],
while antibody is not released, and does not accumulate. To
explore this further, TSn cells were incubated with fluorescently
labeled naked or 39-
BPCNeuAc liposomes at 37uC for the indicated
time, and aliquots of cells were then briefly washed with either
isotonic buffer to assess total bound liposomes, or with acidic
buffer (pH 3.3) that removes surface-bound ligands, revealing the
amount internalized (Figure 2C). At 5 minutes about 1/3 of the
bound liposomes were internalized, but over time the percentage
internalized increases such that nearly 90% is internalized by 60
minutes. The results reinforce our interpretation from Figure 2B
that ligand-decorated cargo accumulates in the cell as a result of
Sn/CD169 releasing the ligands in endosomal compartments, and
recycling to the surface to shuttle additional cargo into the cell as
documented for CD22 [19].
To test the hypothesis that anti-Sn antibody recycles to the cell
surface after internalized by Sn/CD169, we conducted a recycling
experiment analogous to that done to characterize recycling of
CD22 [19]. We first incubated the CHO cells expressing Sn/
CD169 with unlabeled anti-Sn antibody at 37uC. The cells were
washed with acidic buffer to remove bound antibody on the cell
surface (Figure 2D, Top). Acid-washed cells were then incubated
at either 4uC as a control for no recycling (Figure 2D, Middle) or
37uC to allow recycling to occur (Figure 2D, Bottom). Cells were
then stained with secondary anti-rat IgG antibody to detect the
unlabeled antibody that recycled back to the cell surface from
inside the cell. As seen in the bottom panel, internalized anti-Sn
antibody did indeed recycle to the surface of the cell following
incubation at 37uC (Figure 2D, Bottom).
Sn-targeted Liposomes are Delivered to Endosomes and
Lysozymes
Next we analyzed the subcellular localization of 39-
BPCNeuAc
liposomes by fluorescence microscopic analysis using a CHO cell
line expressing Sn/CD169 (Figure 3 and Figure S1). Sn-CHO
cells were exposed to fluorescently labeled liposomes (green) for 90
minutes, and then co-stained with antibodies to Sn/CD169 (top
panels), or to antibodies to markers of early endosomes (EEA-1) or
lysosomes (LAMP1). As expected, control cells stained with non-
targeted ‘naked’ liposomes show little green fluorescence. Howev-
er, cells exposed to 39-
BPCNeuAc liposomes showed robust
punctate staining of intracellular compartments. This is in marked
contrast to the intense cell surface localization of the Sn/CD169
(Figures 3 and S1). The intracellular 39-
BPCNeuAc liposomes
internalized by Sn/CD169 show modest co-localization with early
endosomes, and strong co-localization with lysosomes. These data
suggest that liposomes with 39-
BPCNeuAc ligands are efficiently
endocytosed by Sn-expressing cells, and the glycan ligand-
decorated liposomal cargo accumulates in lysosomes. Despite the
fact that endocytosis of liposomes is mediated by Sn/CD169, there
is little evidence of Sn in intracellular compartments. As discussed
further below, we believe that this reflects the fact that Sn is a
recycling receptor, and is predominately localized at the surface of
the cell.
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BPCNeuAc Liposomes for Human and
Mouse Siglecs
To evaluate the selectively and affinity of the 39-
BPCNeuAc
liposomes to other siglecs, we tested binding of the naked and the
39-
BPCNeuAc liposomes against a panel of siglec-expressing cell
lines. As shown in Figure 4A, 39-
BPCNeuAc liposomes exhibited
strong binding to human and mouse Sn-expressing cells, and little
or no binding cells expressing most other siglecs. The exception
was moderate binding of 39-
BPCNeuAc liposomes to murine
Siglec-G expressing cells, which is expressed on B cells, monocytes
and dendritic cells (Figure 4B) [20–22]. In this regard, it is notable
that they exhibited no detectable binding to cells that express
Siglec-10, the human ortholog of Siglec-G. Binding of the ligand
liposomes to cell lines that express other siglecs was at minimum
levels comparing to that of the non-targeted naked liposomes. To
assess the degree to which 39-
BPCNeuAc liposomes are targeted to
Sn-expressing cells in vivo, we compared the plasma clearance rate
of the naked and 39-
BPCNeuAc liposomes in the wild type or the
Sn
2/2 mouse strain (Figure S2). In contrast to the naked liposomes
that showed no difference in clearance between the two strains,
liposomes with 39-
BPCNeuAc ligands were cleared approximately
8-fold more rapidly in the wild type mice than in the Sn
2/2 mice
at 2 hr post liposome injection, suggesting that they are
predominantly taken up by Sn-expressing cells in the wild type
mice and remain long circulating in the mice that do not express
Sn. Thus, while the 39-
BPCNeuAc ligand exhibits some cross-
reactivity with Siglec-G, rapid clearance of the liposomes from the
blood is mediated primarily by Sn/CD169 expressing cells.
Sn-mediated Binding of Liposomes to Bone Marrow
Derived Macrophages (BMM)s
Macrophages, like dendritic cells, are antigen-presenting cells
(APC) and are capable of degrading extracellular antigens into
fragments and presenting digested peptides along with MHC class
II molecules to CD4
+ T cells. Since Sn/CD169 is a macrophage-
specific surface receptor, we anticipate that Sn/CD169 receptor-
mediated endocytosis could enhance macrophage antigen engulf-
ment and facilitate the MHC II-restricted antigen presentation to
T cells. To demonstrate the feasibility of using Sn-targeted
liposomes as an efficient vehicle that could deliver antigen cargos
to primary macrophages, we examined the binding of
39-
BPCNeuAc liposomes to macrophages that were derived from
mouse bone marrow cells. Upon 7 days culture in vitro
supplemented with M-CSF cytokine, mouse bone marrow cells
differentiated into mature macrophages and expressed surface F4/
80 (Figure 5A and Figure S3). These bone marrow derived
macrophages (BMM)s exhibit a basal level expression of Sn/
CD169 and exhibit weak binding of 39-
BPCNeuAc liposomes. With
an additional 48-hr stimulation with IFN-a, the activated BMMs
exhibited a 4–5 fold increase in surface Sn/CD169 expression,
significantly enhancing the binding of the Sn-targeted liposomes
(Figure 5A and Figure S3). This result is consistent with previous
reports that IFN-a augmented expression of Sn/CD169 on
human and porcine monocytes [14,23]. We confirmed that
binding of the liposomes to IFN-a stimulated BMMs is Sn/
CD169 dependent using BMMs derived from Sn
2/2 strain. As
shown in Figure 5B, 39-
BPCNeuAc liposomes bound only to BMMs
derived from a wild type mouse but not to those derived from an
Sn
2/2 strain whereas the naked liposomes do not exhibited
binding to either. These results indicate that Sn-targeted liposomes
bind selectively to Sn-expressing macrophages in an Sn/CD169-
dependent manner.
Sn-targeted Liposomes Deliver OVA Antigen to BMMs
and Activate OVA-specific CD4
+ T Cells
Since the internalized Sn-targeted liposomes traffic to the
lysosomal compartments of the cell, where the antigen loading to
appropriate MHC II molecules occurs, we investigated whether
Sn-targeted liposomes are capable of delivering antigen cargo to
macrophages and induce subsequent antigen presentation to T
cells. For this purpose, we exploited an ovalbumin (OVA) specific
T cell model. Naı ¨ve or IFN-a activated BMMs were incubated
briefly with free OVA proteins or with naked or Sn-targeted
liposomes that carry OVA proteins, followed by addition of
purified, CFSE-labeled OT-II CD4
+ T cells that are specific to
OVA peptide 323–339 in context of MHC II I-A
b. Since these T
cells are not activated by intact OVA, T cell activation is a direct
Figure 1. Synthesis of the 39-
BPCNeuAc-pegylated lipids. The sialic acid ligand with an ethylamine linker was coupled to an NHS-activated
pegylated lipid.
doi:10.1371/journal.pone.0039039.g001
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and present the antigenic peptide on MHC II at the surface of the
cell.
Three days after in vitro incubation, T cell proliferation was
measured by CFSE dilution using flow cytometry. As shown in
Figure 6, Sn-targeted liposomes delivered OVA efficiently to the
Sn-expressing BMMs, eliciting a significant enhancement in OVA-
specific T cell proliferation (58% proliferated T cells). In contrast,
low levels of proliferation were seen with OVA delivered by naked
liposomes or added free in solution (9.1 and 18.6% proliferation,
respectively). The fact that the Sn-expressing BMMs treated with
the OVA-loaded naked liposomes induced a lower level of T cell
proliferation than those pulsed with an equal amount of free OVA
proteins, is likely due to a shielding effect of the naked liposomes,
preventing other means of uptake such as the recognition of the
high mannose glycans by the mannose receptor [24,25]. Similar
experiments conducted with naive BMMs that express low levels
of Sn/CD169 (Figure 5) showed no significant enhancement of T
cell activation using OVA loaded 39-
BPCNeuAc-liposomes relative
to the non-targeted naked liposomes (data not shown). The results
reveal an enhanced proliferation of OVA-specific T cells by the
Sn-targeted liposomal OVA relative the non-targeted formula-
tions. These observations support our hypothesis that liposomes
with glycan ligands actively deliver antigens to macrophages
through Sn-mediated endocytosis, consequently enhancing the
activation of antigen-specific T cells.
Discussion
Sn/CD169 is a member of the siglec receptor family whose
members are widely expressed on immune cells of man and
mouse, including neutrophils, eosinophils, basophils, monocytes, B
cells, NK cells, macrophages and dendritic cells [7,8,26–28]. The
restricted expression patterns of siglecs on different cell types and
their roles as regulators of immune cell functions, have made them
attractive targets for developing cell-directed therapies [9]. Indeed,
many antibody and immunotoxin based therapeutics that target
siglecs are being developed as a result of their potential for cell-
depletion therapies that treat leukocyte-mediated allergy, autoim-
mune, infectious diseases and neoplasias [5,29–31].
Several reports have demonstrated an alternative approach of
siglec targeting using multivalent displays of their glycan ligands.
Successful examples include targeting B cells with high affinity
glycan ligands of CD22 (Siglec-2) which results in an effective
Figure 2. Liposomes bearing 39-
BPCNeuAc ligands bind to and internalized by Sn/CD169 expressing cells. (A) FACS analysis for binding
of the naked (blue line)o r3 9-
BPCNeuAc (red line) liposomes to TSn and Daudi cells that express surface hSn and hCD22 (Siglec-2), respectively.
Unstained cells (filled grey) were used as a negative control. Shown are results from 1 of 3 representative experiments followed indicated treatment.
(B) Ligand-bound liposomal cargos but not antibodies exhibited time-dependent accumulation in Sn-expressing cells. TSn cells were incubated with
fluorescently labeled anti-Sn antibody (Clone 7–239 (Serotech); filled red, left panel) or Sn-targeted liposomes (filled red, right panel) for 5, 20 and
90 min before they were washed with isotonic HBSS buffer prior to FACS analysis. Isotype antibody or naked liposome stained cells were used as
negative controls. (C) Internalization of Sn-targeted liposomes by TSn cells. Cells were incubated with fluorescent naked or 39-
BPCNeuAc liposomes for
5, 30 or 60 min at 37uC before they were washed with isotonic HBSS buffer (pH 7) or acid buffer (pH 3.3) prior to FACS analysis to determine levels of
the total liposome uptake (membrane bound plus internalized), or internalized liposomes. Cells that were not stained with liposomes were used as a
negative control (filled gray). (D) Recycling of Sn between cell surface and inside the cell. Top; unlabeled anti-Sn Ab was incubated with Sn expressing
CHO cells at 37uC. Cells were then cooled to 4uC and stained with a labeled secondary Ab after a neutral wash (Red line) or acid wash (Orange line)t o
detect residual cell surface bound anti-Sn Ab. Isotype control antibody staining is shown as filled histogram. Middle; acid-washed cells from the Top
were subjected to a further incubation at 4uC and stained with labeled secondary Ab, showing that no anti-Sn Ab had returned to the cell surface.
Bottom; acid-washed cells from the Top were warmed to 37uC to allow internalized anti-Sn Ab to be recycled back to the cell surface. Ab re-appearing
on the surface of the cell is detected by staining the cells with labeled secondary Ab. Results shown are representative of at least two independent
experiments.
doi:10.1371/journal.pone.0039039.g002
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targeting eosinophils using a multivalent glycan ligands of Siglec-8,
which induces apoptosis of eosinophils and could be useful in
controlling eosinophilic inflammatory responses [33].
Sn/CD169 expression is highly restricted to a subset of resident
and activated tissue macrophages [2,34] making it an attractive
receptor for targeting these cells. Recent reports suggest that Sn/
CD169-expressing macrophages in the follicle and subcapsular
sinus and medulla of lymph nodes play an important role in
capturing and processing extracellular antigens and interacting
with immune cells to initiate adaptive immune responses [35–39].
Thus, these cells are interesting targets for inducing an immune
response, and several recent reports demonstrate an enhancement
of an immune response by delivering antigens to them using anti-
Sn/CD169 antibody [5,6].
Here we have demonstrated that Sn/CD169 ligand decorated
nanoparticles is an efficient alternative to the use of anti-Sn
antibody as a means for delivery of antigens to macrophages.
39-
BPCNeuAc-liposomes developed in this study is approximately
100 nm in size, which likely allows Sn/CD169 to utilize the
clathrin-mediated endocytosis as seen in the case of anti-Sn
antibody internalization [5]. A potential advantage of the ligand
targeted-liposomes as a delivery platform is their accumulation in
lysosomes. Indeed, the sub-cellular localization of the endocytosed
ligand-decorated liposomes in lysosomes is in contrast to the
subcellular localization of anti-Sn antibody studied by Delputte et
al. [5], where the majority of the antibody remained on the surface
of the cell, and endocytosed antibody was found only in early
endosomes, never in lysosomes. We believe that these results are
completely consistent with ours, and reflect the fact that Sn is a
recycling receptor, where at anytime, most of the Sn/CD169 is
extracellular. Once endocytosed by Sn/CD169, the ligand
decorated liposomes and antibody are handled differently. In
analogy to what we have found for CD22 [19], we suggest that the
ligand-decorated liposomes are released in the acidic endosomes,
and then traffic to lysosomes. In contrast, antibody is not efficiently
released, and tracks the subcellular localization of Sn/CD169.
Thus, as shown by Delputte et al, anti-Sn remains predominately
on the outside of the cell, and is found only in early endosomes.
The fact that the ligand-targeted liposomes are released and
accumulate in endosomal compartments is a potential advantage
for the use of this platform for delivery of antigens to macrophages.
However, studies comparing several different commercial sources
of anti-human Sn and anti-murine Sn showed that some
antibodies do not accumulate (Figure 2B), while others slowly
Figure 3. Fluorescence microscopy analysis of the endocytosis
of 39-
BPCNeuAc liposomes in the Sn-expressing cells. CHO-mSn/
CD169 cells were stained with fluorescently labeled naked or
39-
BPCNeuAc liposomes (green) followed by staining with anti-Sn (red)
or antibodies that detect early endosomes (red) and lysosomes (red).
The nuclei were visualized by staining with DAPI (blue).
doi:10.1371/journal.pone.0039039.g003
Figure 4. Specificity of Sn-targeted liposomes against a panel of siglec-expressing cells. FACS analysis for binding of naked or
39-
BPCNeuAc liposomes to siglec-expressing CHO lines and TSn and BW5147 cell lines that express hSn and Siglec-G, respectively. (A) Binding of
liposomes is expressed as mean channel fluorescence (MCF) 6 s.d. (n=3). Binding degree of 39-
BPCNeuAc liposomes to TSn, CHO-mSn cells was
statistically significant comparing to the same cell line that was treated with the naked liposomes (*P,0.05). (B) Compatible amount of 39-
BPCNeuAc
liposome binding to CHO-mSn and SIglec-G-BW5147 cells is shown. Cells were stained with 39-
BPCNeuAc (Red), Naked liposomes (Gray), or unstained
(Black). Data are representative of 2 independent experiments.
doi:10.1371/journal.pone.0039039.g004
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antibodies in endosomes may be antibody dependent (data not
shown).
The idea of targeting antigens to immune cells using receptors
that recognize carbohydrate ligands has been investigated by
several laboratories [24,25,40–45]. A good example is dendritic
cell-specific intercellular adhesion molecule-3 grabbing noninte-
grin (DC-SIGN) which is characterized as the most dendritic cell
restricted C-type lectin receptor (CLR). The DC-SIGN functions
as an antigen uptake receptor and has a high affinity for both
fucose and mannose containing glycans. Recent studies from van
Kooyk’s group using a human DC-SIGN transgenic mouse model
showed that OVA modified with glycans that specifically target
DC-SIGN induces a 7,10-fold increase of CD4 T cell prolifer-
ation and a 2-fold enhancement in proliferation of CD8 T cells
[44]. The same group also reported that alteration of glycosylation
on the melanoma antigen gp100 with high-mannose structures
target DC-SIGN on monocyte-derived dendritic cells, resulting in
enhanced antigen presentation to T cells [40]. As macrophages
also play an important role in innate and adaptive immune
response, several reports have shown that targeting mannosylated
Figure 5. Sn-targeted liposomes bind to IFN-a stimulated bone marrow derived macrophages (BMM)s. (A) Mature macrophages
differentiated from wild type mouse bone marrow cells were stimulated with IFN-a or left untreated before staining with anti-Sn, anti-F4/80
antibodies (filled gray) and Sn-targeted liposomes (filled gray). Cells were thoroughly washed prior to FACS analysis. Isotype antibody or naked
liposome stained cells were used as negative controls (black lines). (B) BMMs derived from wild type or Sn
2/2 mice were stained with fluorescent
naked (blue lines) or Sn-targeted (filled red) liposomes prior to FACS analysis. Unstained cells (black lines) were used as a negative control. Data are
representative of 3 independent experiments.
doi:10.1371/journal.pone.0039039.g005
Figure 6. Antigen delivery to BMMs using Sn-targeted liposomes led to proliferation of antigen-specific T cells. Sn-expressing BMMs
(stimulated by IFN-a) were treated with free OVA proteins, naked or Sn-targeted liposomes that carry OVA for 1 hr or left untreated as a negative
control. CD4
+ T cells purified from OT-II transgenic mice were CFDA labeled and incubated with the washed BMMs that were treated with indicated
conditions. After 72 hr culture in vitro, T cells were harvested and analyzed for CFDA dilution by flow cytometry. Percentages of the dividing CD4
+ T
cells are indicated. Shown are representative of 2 independent experiments.
doi:10.1371/journal.pone.0039039.g006
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antigen uptake and presentation by macrophages [24,40–42,45].
A limitation in the interpretation of results from in vivo targeting
of antigens to antigen-presenting cells using ligands of glycan-
binding proteins is the overlap in the ligand specificity of these
receptors, and the degree to which they are expressed on single
types of antigen presenting cells. Thus, for example, mannose
containing glycans recognized by MMR and the Lewis X
structures recognized by DC-SIGN are also recognized by other
C-type lectins expressed on dendritic cells and macrophages
[46,47]. Ideally the ligand would be specific for a single receptor,
allowing investigations into the efficiency of targeting antigens via
that receptor and establishing which cells are contributing to an
immune response.
In this report we document a novel platform for delivery of
antigens to macrophages comprising liposomal nanoparticles
decorated with high affinity glycan ligands of Sn/CD169, a
macrophage specific membrane receptor. Antigens targeted to
bone marrow derived macrophages induce robust Sn/CD169
dependent activation of antigen specific T cells. Although in vivo
studies show that the ligand-targeted liposomes are primarily
cleared via Sn/CD169 macrophages (Figure S2), and preliminary
studies using targeted liposome bearing antigens show dramati-
cally enhanced immune response, the response is not strictly Sn/
CD169 dependent (data not shown). We attribute this to the cross-
reactivity of the ligand with Siglec-G (Figure 4B) that is expressed
on other antigen presenting cells (e.g. dendritic cells and B cells).
Thus, more specific ligands are required to perform definitive
studies evaluating the potential of Sn/CD169 targeted liposomes
in vivo.
Supporting Information
Figure S1 Confocal microscopy reveals surface locali-
zation of Sn. CHO cells expressing hSn were detected by anti-Sn
(green) antibody and were co-stained with antibodies that detect
early endosomes (red) or lysosomes (red). The nuclei were
visualized by staining cells with DAPI (blue). See Methods S1.
(DOCX)
Figure S2 Sn-targeted liposomes in the plasma are
cleared faster in the wild-type animals than in the
Sn2/2 mice. Wild type C57BL/6 (filled symbols) and Sn2/2
(open symbols) mice (n=3) were i.v. injected with naked (circles)
or 39-BPCNeuAc (triangles) liposomes that encapsulate equal
amount of doxorubicin. Plasma samples were collected from mice
at indicated time points and analyzed for the remaining
doxorubicin concentration in the plasma comparing to the initial
injection dose. These studies were done as part of a larger study, a
portion of which has been published (see References in Methods
S1), including the results with the naked liposomes that serve as the
control group in this experiment.
(DOCX)
Figure S3 Sn-targeted liposomes bind to IFN-a stimu-
lated BMM. (A) Histograms of F4/80 expression on the mature
BMM that were stimulated with indicated cytokines followed by
staining with FITC-conjugated anti-mouse F4/80 (filled blue) or
isotype (light gray) antibodies prior to FACS analysis. Percentages
of myeloid-gated F4/80+ BMM are indicated. (B) Cytokine-
stimulated BMM were compared for binding of fluorescent 39-
BPCNeuAc liposomes (filled green) and naked liposomes (light
gray). Percentages of 39-BPCNeuAc liposomes bound BMM are
indicated.
(DOCX)
Methods S1 Confocal microscopy and pharmacokinetic
study.
(DOC)
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